Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements - Contingent Consideration (Details)

v3.24.3
Fair Value Measurements - Contingent Consideration (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Jan. 11, 2024
Jun. 21, 2023
Mar. 31, 2024
Sep. 30, 2024
Sep. 30, 2023
Jun. 03, 2024
Dec. 31, 2023
Fair Value Measurements              
Exarafenib milestone contingent consideration (Note 4)       $ 3,125      
Contingent consideration under RPAs, AAAs and CPPAs       4,000     $ 7,000
Payments of consideration under RPAs, AAAs and CPPAs       37,000 $ 14,650    
LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement              
Fair Value Measurements              
Contingent consideration under RPAs, AAAs and CPPAs       1,000      
Payments of consideration under RPAs, AAAs and CPPAs   $ 5,000          
Contingent consideration, high-end of range       0      
LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement | Regulatory milestones              
Fair Value Measurements              
Contingent consideration under RPAs, AAAs and CPPAs   1,000 $ 0 0   $ 0 $ 1,000
Payments of consideration under RPAs, AAAs and CPPAs $ 1,000   $ 1,000 $ 1,000      
Contingent consideration, high-end of range   $ 5,000